MD1591B2 - Derivaţi ai peptidelor cu activitate terapeutică - Google Patents

Derivaţi ai peptidelor cu activitate terapeutică

Info

Publication number
MD1591B2
MD1591B2 MD96-0137A MD960137A MD1591B2 MD 1591 B2 MD1591 B2 MD 1591B2 MD 960137 A MD960137 A MD 960137A MD 1591 B2 MD1591 B2 MD 1591B2
Authority
MD
Moldova
Prior art keywords
peptides
derivatives
biologic
peptides derivatives
therapeutic activity
Prior art date
Application number
MD96-0137A
Other languages
English (en)
Russian (ru)
Other versions
MD960137A (ro
Inventor
Sun Hyuk Kim
Zhengxin Dong
John E Taylor
Sylviane Moreau
Susan Riley Keyes
Original Assignee
Biomeasure, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomeasure, Inc. filed Critical Biomeasure, Inc.
Publication of MD960137A publication Critical patent/MD960137A/ro
Publication of MD1591B2 publication Critical patent/MD1591B2/ro

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C07K7/086—Bombesin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C07K14/6555—Somatostatins at least 1 amino acid in D-form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)

Abstract

Invenţia se referă la derivaţii peptidelor biologic active, utilizate în medicină, în special în oncologie.Problema pe care o rezolvă invenţia constă în crearea unor derivaţi ai peptidelor cu o activitate biologică înaltă şi de lungă durată, utili pentru tratamentul cancerului.Derivaţii peptidelor biologic active, conform invenţiei, conţin unul sau câţiva substituenţi ciclici sau aciclici, care includ radicali de diferită natură chimică şi cel puţin una din peptide este unită cu fiecare din substituenţi prin legătura CO-N, CH2-N sau SO2-N între substituent şi atomul de azot N-terminal sau al lanţului lateral al uneia din peptide.Derivaţii peptidelor astfel modificaţi au o activitate biologică mai înaltă şi de lungă durată şi pot fi utilizaţi în cantităţi terapeutice pentru tratamentul cancerului.
MD96-0137A 1993-08-09 1994-08-08 Derivaţi ai peptidelor cu activitate terapeutică MD1591B2 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10419493A 1993-08-09 1993-08-09
PCT/US1994/008875 WO1995004752A1 (en) 1993-08-09 1994-08-08 Therapeutic peptide derivatives

Publications (2)

Publication Number Publication Date
MD960137A MD960137A (ro) 1999-01-31
MD1591B2 true MD1591B2 (ro) 2001-01-31

Family

ID=22299154

Family Applications (1)

Application Number Title Priority Date Filing Date
MD96-0137A MD1591B2 (ro) 1993-08-09 1994-08-08 Derivaţi ai peptidelor cu activitate terapeutică

Country Status (30)

Country Link
US (1) US5552520A (ro)
EP (3) EP1288223B1 (ro)
JP (3) JP3618750B2 (ro)
KR (1) KR100325972B1 (ro)
CN (1) CN1055700C (ro)
AT (3) ATE284413T1 (ro)
AU (1) AU689490B2 (ro)
CA (1) CA2168113C (ro)
CZ (3) CZ292586B6 (ro)
DE (3) DE69435105D1 (ro)
DK (3) DK1288224T3 (ro)
ES (3) ES2309131T3 (ro)
FI (1) FI960584A (ro)
GE (1) GEP20002146B (ro)
HK (2) HK1053313A1 (ro)
HU (1) HU224350B1 (ro)
LT (1) LT4078B (ro)
LV (1) LV11549B (ro)
MD (1) MD1591B2 (ro)
NZ (1) NZ271238A (ro)
PL (1) PL180612B1 (ro)
PT (2) PT1288223E (ro)
RO (1) RO117259B1 (ro)
RU (1) RU2133252C1 (ro)
SG (1) SG75092A1 (ro)
SI (2) SI9420051A (ro)
SK (1) SK15096A3 (ro)
UA (1) UA44707C2 (ro)
WO (1) WO1995004752A1 (ro)
ZA (1) ZA945966B (ro)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD2074G2 (ro) * 2000-12-29 2003-06-30 Юрий НИКИТИН Procedeu şi instalaţie de captare a vaporilor de carburant la staţiile de alimentare cu petrol, condensator al vaporilor de carburant utilizat în instalaţia menţionată

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2774769B2 (ja) * 1993-04-26 1998-07-09 賢治 寒川 アドレノメデュリン
CA2190633A1 (en) * 1995-03-20 1996-09-26 Kenji Shibata Novel calcitonin derivatives
US5824772A (en) * 1995-04-04 1998-10-20 Advanced Bioconcept, Inc. Fluorescent somatostatin
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6479457B2 (en) * 1995-06-06 2002-11-12 Kinerton Limited Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides
US5830431A (en) * 1995-06-07 1998-11-03 Mallinckrodt Medical, Inc. Radiolabeled peptide compositions for site-specific targeting
US7410948B2 (en) 1995-07-13 2008-08-12 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Analogs of parathyroid hormone
US6544949B1 (en) 1995-07-13 2003-04-08 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Analogs of parathyroid hormone
US5766620A (en) * 1995-10-23 1998-06-16 Theratech, Inc. Buccal delivery of glucagon-like insulinotropic peptides
US7078413B2 (en) 1996-04-19 2006-07-18 Wisconsin Alumni Research Foundation Compositions and methods of use for a bombesin peptide
US6492330B1 (en) * 1996-08-16 2002-12-10 National Institute Of Immunology Antiangiogenic drugs
US5968903A (en) * 1998-05-07 1999-10-19 Biomeasure, Incorporated Inhibition of H. pylori proliferation
US6124263A (en) * 1998-11-16 2000-09-26 Asta Medica Ag Treatment of tumors by administration of growth hormone releasing compounds and their antagonists
US6864234B1 (en) 1999-06-25 2005-03-08 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Somatostatin agonists
WO2001000676A1 (en) * 1999-06-25 2001-01-04 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Somatostatin agonists
AU2004200688B2 (en) * 1999-08-18 2007-01-25 Ipsen Pharma S.A.S. Sustained release formulation of a peptide
EP1348444B1 (en) * 1999-08-18 2006-04-12 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Sustained release formulation of a peptide complexed with a polymer
PT1204429E (pt) * 1999-08-18 2004-02-27 Conseils De Rec Appl Scient S Formulacao de libertacao prolongada de um peptido
IES990700A2 (en) 1999-08-18 2001-08-22 Kinerton Ltd Process to make a sustained release formulation
US7109166B1 (en) 1999-08-18 2006-09-19 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Sustained release formulation of a peptide
GB0018891D0 (en) 2000-08-01 2000-09-20 Novartis Ag Organic compounds
US6316414B1 (en) 2000-07-31 2001-11-13 Dabur Research Foundation Somatostatin analogs for the treatment of cancer
EP1390406B1 (en) 2001-03-06 2007-05-16 Il Consorzio Ferrara Richerche Method of modulating the proliferation of medullary thyroid carcinoma cells
DE60226419D1 (de) * 2001-03-08 2008-06-19 Univ Tulane Somatostatin-antagonisten
US20030229013A1 (en) * 2001-12-07 2003-12-11 Shih-Kwang Wu Solid phase method for synthesis peptide-spacer-lipid conjugates, conjugates synthesized thereby and targeted liposomes containing the same
FR2833596B1 (fr) * 2001-12-14 2005-02-18 Aventis Pharma Sa Procede de preparation de derives d'echinocandine
US20040171070A1 (en) * 2002-05-20 2004-09-02 Ramagauri Bhikhabhai Peptide analysis using a solid support
JP2006516262A (ja) 2002-12-17 2006-06-29 ナステック・ファーマシューティカル・カンパニー・インコーポレーテッド Ｙ２受容体結合ペプチドの粘膜送達促進のための組成物および方法ならびに肥満症の治療法および予防法
US7229966B2 (en) 2002-12-17 2007-06-12 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity
US7166575B2 (en) 2002-12-17 2007-01-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
US7186692B2 (en) 2002-12-17 2007-03-06 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20090220587A1 (en) * 2005-02-01 2009-09-03 United State Army Liposomal drug delivery constructs targeted by lipid-conjugated peptide ligands
US7741431B2 (en) * 2005-02-01 2010-06-22 The United States Of America As Represented By The Secretary Of The Army Liposomes containing novel targeting and/or fusogenic peptides, preparations containing them and therapeutic use thereof
BRPI0616463A2 (pt) 2005-09-29 2011-06-21 Merck & Co Inc composto, composição farmacêutica, e, uso de um composto
CA2664113C (en) 2006-09-22 2013-05-28 Merck & Co., Inc. Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer
EP2118123B1 (en) 2007-01-31 2015-10-14 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
WO2008121767A2 (en) 2007-03-28 2008-10-09 President And Fellows Of Harvard College Stitched polypeptides
CA2682727C (en) 2007-04-02 2016-03-22 Banyu Pharmaceutical Co., Ltd. Indoledione derivative
EP2310029B1 (en) 2008-06-12 2019-04-03 Ipsen Bioinnovation Limited Fusion proteins for use in the treatment of cancer
CN102112145B (zh) 2008-06-12 2014-07-30 辛它可辛有限公司 神经内分泌病的抑制
GB0820970D0 (en) 2008-11-17 2008-12-24 Syntaxin Ltd Suppression of cancer
WO2010107486A2 (en) * 2009-03-18 2010-09-23 The Board Of Trustees Of The Leland Stanford Junior University Use of somatostatin or an analogue thereof in combination with external radiation therapy
EP3735944A1 (en) 2009-09-28 2020-11-11 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
BR112012012945A2 (pt) 2009-11-25 2020-12-29 Arisgen Sa Composição de liberação mucosal, seu método de produção, complexo de peptídeo pré-formado, kit e uso de um agente ativo de peptídeo
CA2786181C (en) 2010-01-13 2017-12-12 Ipsen Pharma S.A.S. Process for the preparation of pharmaceutical compositions for the sustained release of somatostatin analogs
CN102260352B (zh) * 2010-05-28 2013-11-20 山东先声麦得津生物制药有限公司 靶向性白细胞介素融合蛋白及其制备方法与应用
EP2399931A1 (fr) * 2010-06-22 2011-12-28 Ipsen Pharma S.A.S. Nouveaux composés octapeptidiques et leur utilisation thérapeutique
WO2012021876A2 (en) 2010-08-13 2012-02-16 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
AU2012326026B2 (en) 2011-10-18 2017-04-13 Aileron Therapeutics, Inc. Peptidomimetic macrocyles
KR102112373B1 (ko) 2012-02-15 2020-05-18 에일러론 테라퓨틱스 인코포레이티드 펩티드모방체 마크로사이클
US8987414B2 (en) 2012-02-15 2015-03-24 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
SG11201503052RA (en) 2012-11-01 2015-05-28 Aileron Therapeutics Inc Disubstituted amino acids and methods of preparation and use thereof
WO2016049359A1 (en) 2014-09-24 2016-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
AU2016235424A1 (en) 2015-03-20 2017-10-05 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
WO2017200943A1 (en) 2016-05-16 2017-11-23 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
CN108659100A (zh) * 2017-03-28 2018-10-16 上海新生源医药集团有限公司 具有镇痛作用的多肽及其应用
WO2020077129A1 (en) 2018-10-11 2020-04-16 Intarcia Therapeutics, Inc. Human amylin analog polypeptides and methods of use
KR20220017695A (ko) * 2020-08-05 2022-02-14 주식회사 레미바이오 아스코르브산 유도체 및 이를 포함하는 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988002756A2 (en) * 1986-10-13 1988-04-21 Sandoz Ag Peptide derivatives
US4837303A (en) * 1985-06-25 1989-06-06 Diamalt Aktiengesellschaft Novel somatostatin derivatives
WO1989009786A1 (en) * 1988-04-08 1989-10-19 Sandoz Ag Peptide derivatives

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1246055A (en) * 1980-03-24 1988-12-06 Joseph H. Cort N-.omega.-substituted hormonogens of vasopressin and its synthetic analogs
DE3614833A1 (de) 1986-01-16 1987-07-23 Hoechst Ag Peptide mit vasorelaxierender, natriuretischer und diuretischer wirkung, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung
DK375789A (da) 1988-08-18 1990-02-19 Syntex Inc Peptidderivater
FR2638968B1 (fr) 1988-11-11 1994-10-07 Sandoz Sa Nouvelle utilisation therapeutique de la somatostatine et de ses analogues et derives
DE69024230T2 (de) * 1989-12-22 1996-05-02 Commw Scient Ind Res Org An fette gebundene aminosäuren, peptide oder deren derivate
GB9209032D0 (en) * 1992-04-25 1992-06-10 Ciba Geigy Ag New peptide derivatives

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837303A (en) * 1985-06-25 1989-06-06 Diamalt Aktiengesellschaft Novel somatostatin derivatives
WO1988002756A2 (en) * 1986-10-13 1988-04-21 Sandoz Ag Peptide derivatives
WO1989009786A1 (en) * 1988-04-08 1989-10-19 Sandoz Ag Peptide derivatives

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD2074G2 (ro) * 2000-12-29 2003-06-30 Юрий НИКИТИН Procedeu şi instalaţie de captare a vaporilor de carburant la staţiile de alimentare cu petrol, condensator al vaporilor de carburant utilizat în instalaţia menţionată

Also Published As

Publication number Publication date
CZ292586B6 (cs) 2003-10-15
CA2168113C (en) 2002-10-01
US5552520A (en) 1996-09-03
RU2133252C1 (ru) 1999-07-20
JP3785179B2 (ja) 2006-06-14
HK1053314A1 (en) 2003-10-17
EP0788509B1 (en) 2003-05-28
EP0788509A4 (en) 1999-07-14
AU7481994A (en) 1995-02-28
RO117259B1 (ro) 2001-12-28
PL312989A1 (en) 1996-05-27
PL180612B1 (pl) 2001-03-30
HU224350B1 (hu) 2005-08-29
NZ271238A (en) 1997-10-24
JP3618750B2 (ja) 2005-02-09
MD960137A (ro) 1999-01-31
SI9420051A (en) 1996-12-31
CZ39096A3 (en) 1996-11-13
KR100325972B1 (ko) 2002-07-27
DE69434181D1 (de) 2005-01-13
HUT73491A (en) 1996-08-28
DE69435105D1 (de) 2008-08-07
EP1288224A1 (en) 2003-03-05
SI0788509T1 (en) 2003-10-31
LT96025A (en) 1996-07-25
JP3869439B2 (ja) 2007-01-17
DE69432758D1 (en) 2003-07-03
ATE241643T1 (de) 2003-06-15
CA2168113A1 (en) 1995-02-16
DK0788509T3 (da) 2003-06-23
CN1133047A (zh) 1996-10-09
DE69432758T2 (de) 2004-02-19
EP1288224B1 (en) 2008-06-25
ES2309131T3 (es) 2008-12-16
WO1995004752A1 (en) 1995-02-16
SG75092A1 (en) 2000-09-19
AU689490B2 (en) 1998-04-02
LV11549B (en) 1997-04-20
LT4078B (en) 1996-12-27
CZ289590B6 (cs) 2002-02-13
HK1053313A1 (en) 2003-10-17
HU9600281D0 (en) 1996-04-29
LV11549A (lv) 1996-10-20
FI960584A0 (fi) 1996-02-08
DE69434181T2 (de) 2005-12-01
GEP20002146B (en) 2000-06-25
ZA945966B (en) 1995-06-26
EP0788509A1 (en) 1997-08-13
PT788509E (pt) 2003-10-31
EP1288223B1 (en) 2004-12-08
ES2229045T3 (es) 2005-04-16
FI960584A (fi) 1996-02-08
ES2196031T3 (es) 2003-12-16
JPH09501177A (ja) 1997-02-04
PT1288223E (pt) 2005-03-31
DK1288224T3 (da) 2008-10-13
CN1055700C (zh) 2000-08-23
CZ289552B6 (cs) 2002-02-13
EP1288223A1 (en) 2003-03-05
SK15096A3 (en) 1996-07-03
JP2004339237A (ja) 2004-12-02
ATE284413T1 (de) 2004-12-15
UA44707C2 (uk) 2002-03-15
JP2005015488A (ja) 2005-01-20
ATE399177T1 (de) 2008-07-15
DK1288223T3 (da) 2005-03-29

Similar Documents

Publication Publication Date Title
MD1591B2 (ro) Derivaţi ai peptidelor cu activitate terapeutică
DE69715888D1 (de) Pyridylalken- und pyridylalkin-säureamide als cytostatika und immunosuppressive arzneimittel
UA32429C2 (uk) Засіб для лікування нетримання сечі
DK65293A (da) Fremgangsmåde til administrering af taxol
CY2123B1 (en) Isoxazole-4-carboxamides and hydroxyalkylidene-cyanoacetamides drugs containing these compounds and use of such drugs
MY129973A (en) Sulphonylbenzyl-substituted pyridones.
IL107109A0 (en) Compounds for modifying drug resistance and pharmaceutical compositions containing the same
NO951740D0 (no) Preparater av eikebarkekstrakt, beslektede syntetiske preparater og fremgangsmåte for anvendelse av disse
DE69426334D1 (de) Parenterales Busulfan zur Behandlung von malignen Krankheiten
IL86633A (en) 2-furanone derivatives, their preparation and pharmaceutical compositions containing them
ES2002053A6 (es) Procedimiento para la obtencion de peptidos inihiobidores de renina que contienen grupos hidroxi.
DK0668077T3 (da) Produkter, som indeholder G-CSF og TNF-bindende protein
DE69427485D1 (de) Verbindungen, zubereitungen und behandlung von allergien und entzündungen
ES2058343T3 (es) Piridinas disubstituidas.
ATE139440T1 (de) Behandlung von entzündlichen darmerkrankungen
BG50159A3 (en) Method for preparing derivatives of piranobenzadiasole
MX9304626A (es) Derivados heterociclicos utiles en el tratamiento de enfermedades cardiovasculares.
DE69330960D1 (de) Normalisierer der blutkoagulation enthaltend tcf-ii als aktiven bestandteil
DE69129693D1 (de) Verwendung von nickel und bromide ionen für die behandlung von psoriasis
DE59305285D1 (de) Transdermales therapeutisches system mit pentylentetrazol als wirkstoff
ATE222255T1 (de) 14-substituierte marcfortine und derivate als antiparasitäre mittel
GB1525844A (en) 2-carbamoyl-1,2,4,5-tetrahydro-3h-2-benzazepin-3-ones
UA16000A1 (uk) Спосіб лікуваhhя гіпотрофії поросят
UA50329A (uk) Спосіб лікування первинної бешихи
UA18224A (uk) Спосіб лікуваhhя дерматозів

Legal Events

Date Code Title Description
PD99 Pending application